Smith Group Asset Management LLC Invests $362,000 in DaVita Inc. $DVA

Smith Group Asset Management LLC acquired a new position in shares of DaVita Inc. (NYSE:DVA) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 2,355 shares of the company’s stock, valued at approximately $362,000.

Several other institutional investors have also recently bought and sold shares of the company. Root Financial Partners LLC boosted its position in DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares during the last quarter. Caitlin John LLC acquired a new stake in shares of DaVita in the fourth quarter valued at approximately $34,000. Canada Pension Plan Investment Board bought a new stake in shares of DaVita in the second quarter worth $43,000. Sankala Group LLC bought a new stake in shares of DaVita in the fourth quarter worth $39,000. Finally, iSAM Funds UK Ltd acquired a new position in DaVita during the third quarter worth $46,000. Institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

DVA stock opened at $240.59 on Thursday. DaVita Inc. has a one year low of $101.00 and a one year high of $244.49. The stock has a market cap of $15.45 billion, a price-to-earnings ratio of 22.32, a price-to-earnings-growth ratio of 0.78 and a beta of 0.88. The company has a fifty day moving average price of $216.12 and a two-hundred day moving average price of $171.76.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. The company had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company’s revenue was up 6.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts anticipate that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Insider Activity

In other news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and lifted their price target for the company from $126.00 to $220.00 in a research note on Wednesday, May 6th. Truist Financial increased their price objective on shares of DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. UBS Group raised their price objective on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. TD Cowen lifted their target price on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research report on Monday, May 11th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and a consensus target price of $216.50.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.